Skip to content

13F-HR/A filed by RTW INVESTMENTS, LP

RTW INVESTMENTS, LP filed this 13F-HR/A for the quarter ended 2015-12-31, filed 2016-05-24, with 29 holding rows worth $302,757,000.

Accession
0001493152-16-010244
Filed
2016-05-24
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2015

A holdings report, amendment of type restatement, 29 entries on the cover page, a total value of $302,757,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $302,756,000 with VALUE read as thousands by filing date, 13F file number 028-16670. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock573,361$53,976,000thousands by filing date
LA JOLLA PHARMACEUTICAL CO503459604COM PAR $.0001 21,084,416$29,279,000thousands by filing date
OMEROS CORP682143102COM1,819,341$28,618,000thousands by filing date
KITE PHARMA INC49803L109COM418,935$25,815,000thousands by filing date
DICERNA PHARMACEUTICALS INC253031108COM2,012,662$23,890,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM1,988,914$21,460,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock2,010,501$20,748,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM385,456$12,180,000thousands by filing date
ATARA BIOTHERAPEUTICS INC COM NEW046513107Stock433,923$11,460,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock257,236$10,675,000thousands by filing date
AGENUS INC00847G705COM NEW2,214,453$10,054,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B103COM637,238$9,992,000thousands by filing date
SYMMETRY SURGICAL INC87159G100COM879,623$8,093,000thousands by filing date
Bristol-Myers Squibb Company110122108COM109,701$7,546,000thousands by filing date
CORIUM INTL INC21887L107COM743,865$6,040,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM175,156$5,663,000thousands by filing date
DYAX CORP26746E103COM115,795$4,356,000thousands by filing date
REGENXBIO INC75901B107COM221,326$3,674,000thousands by filing date
LIPOCINE INC NEW53630X104CMN220,515$2,851,000thousands by filing date
Accelerate Diagnostics00430H102COM107,467$2,309,000thousands by filing date
INVUITY INC46187J205COM NEW202,808$1,789,000thousands by filing date
CYTRX CORP232828509COM PAR $.001470,576$1,247,000thousands by filing date
BIOPHARMX CORP09072X101COM370,636$563,000thousands by filing date
NIVALIS THERAPEUTICS INC65481J109COM30,000$232,000thousands by filing date
MERIDIAN BIOSCIENCE INC589584101COMMON STOCK1,252$110,000thousands by filing datecall
ADAPTIMMUNE THERAPEUTICS PLC00653A107SPONDS ADR7,055$85,000thousands by filing date
NEVRO CORP64157F103COM142$37,000thousands by filing dateput
Berkshire Hathaway Inc084670702COM50$7,000thousands by filing date
UNITED STATES OIL FUND LP91232N108UNITS13,850$7,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-16-007396 superseded2016-02-16acceptance time not in the bulk data set
13F-HR/A 0001493152-16-010244this filing2016-05-24acceptance time not in the bulk data set
13F-HR/A 0001493152-16-010245 added2016-05-24acceptance time not in the bulk data set